Ipsen, Santhera deal

Ipsen received exclusive rights to develop and commercialize Santhera's fipamezole ( JP-1730) outside of the U.S., Canada and Japan. Under the deal, Ipsen gains rights to use data generated by Biovail Corp. (TSX:BVF; NYSE:BVF, Mississauga, Ontario), which has U.S. and Canadian rights to fipamezole under an August 2009 deal. Biovail plans to start Phase III testing in 2011 to treat dyskinesia in patients with Parkinson's disease (PD) (see BioCentury, Aug. 31, 2009). ...